We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

98 hedge funds and large institutions have $793M invested in Theravance Biopharma in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 21

0.21% more ownership

Funds ownership: 86.4% → 86.61% (+0.21%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 104 → 98 (-6)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

28% less capital invested

Capital invested by funds: $1.1B → $793M (-$306M)

87% less call options, than puts

Call options by funds: $2.26M | Put options by funds: $17.3M

Holders
98
Holders Change
-6
Holders Change %
-5.77%
% of All Funds
2.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
38
Reduced
21
Closed
15
Calls
$2.26M
Puts
$17.3M
Net Calls
-$15M
Net Calls Change
-$1.97M

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$9.35M
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$5.23M
3
N
Nuveen
North Carolina
+$4.48M
4
JG
Jefferies Group
New York
+$4.37M
5
Nomura Holdings
Nomura Holdings
Japan
+$3.04M

Top Sellers

Rank Fund Capital Flow
1
WIM
Woodford Investment Management
United Kingdom
-$24.7M
2
Morgan Stanley
Morgan Stanley
New York
-$2.6M
3
JP Morgan Chase
JP Morgan Chase
New York
-$2.18M
4
First Trust Advisors
First Trust Advisors
Illinois
-$1.88M
5
OWIM
Old West Investment Management
California
-$1.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$2.4M -$72.1K -3,558 -2%
Barclays
27
Barclays
United Kingdom
$1.8M +$1.34M +66,146 +150%
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$1.7M +$2.1M +103,490 +28,276%
RA
29
Royce & Associates
New York
$1.52M – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$1.48M -$2.18M -107,362 -54%
CM
31
Caption Management
Oklahoma
$1.31M +$1.37M +67,500 +540%
Swiss National Bank
32
Swiss National Bank
Switzerland
$1.26M -$68.9K -3,400 -4%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$1.11M +$26.8K +1,321 +2%
AllianceBernstein
34
AllianceBernstein
Tennessee
$1.03M – – –
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$1.02M +$152K +7,515 +14%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$1.02M +$109K +5,400 +9%
Group One Trading
37
Group One Trading
Illinois
$973K +$972K +47,991 +415%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$932K +$37.9K +1,870 +3%
Squarepoint
39
Squarepoint
New York
$915K +$783K +38,656 +222%
CEP
40
Chicago Equity Partners
Illinois
$867K -$4.05K -200 -0.4%
VEA
41
Virtus ETF Advisers
New York
$829K +$449K +22,139 +77%
EGM
42
Engineers Gate Manager
New York
$694K +$860K +42,471 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$687K – – –
CC
44
Clearline Capital
New York
$608K +$755K +37,258 New
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$587K +$728K +35,946 New
NSEDCP
46
NJ State Employees Deferred Compensation Plan
New Jersey
$508K – – –
CSS
47
Cubist Systematic Strategies
Connecticut
$473K +$317K +15,627 +117%
State Board of Administration of Florida Retirement System
48
State Board of Administration of Florida Retirement System
Florida
$469K +$2.43K +120 +0.4%
AIG
49
American International Group
New York
$459K +$10.4K +515 +2%
Deutsche Bank
50
Deutsche Bank
Germany
$446K -$587K -28,951 -51%
1
2
3 4 5

TBPH Hedge Fund Activity: Q2 2019 in Review

98 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2019, worth a combined $793M — down 28% from $1.1B a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TBPH and 11 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 38 added.

The largest buyer was Ameriprise, opening a new position worth an estimated $9.35M. The largest seller was Woodford Investment Management, cutting an estimated $24.7M.

  • 98 institutional investors held Theravance Biopharma (TBPH) as of Q2 2019, down from 104 in Q1 2019.
  • Funds reported $793M of Theravance Biopharma stock for Q2 2019, down 28% quarter-over-quarter.
  • 11 funds opened new Theravance Biopharma positions in Q2 2019 and 15 closed out, a net change of -4 holders.
  • The largest Theravance Biopharma buyer in Q2 2019 was Ameriprise, an estimated $9.35M added.
  • The largest Theravance Biopharma seller in Q2 2019 was Woodford Investment Management, an estimated $24.7M sold.

Based on aggregated 13F filings for Q2 2019.